Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run

Gilead Sciences (GILD) has emerged as a top-performing healthcare stock in 2025, with shares up 36% year-to-date and reaching record highs, significantly outperforming broader markets. This strong momentum is attributed to robust Q2 results, upwardly revised guidance, and a resilient HIV portfolio, further bolstered by favorable regulatory outcomes and extended exclusivity for key drugs like Biktarvy. Analysts maintain a buy rating, citing attractive valuation and technical indicators that suggest substantial near-term and long-term upside potential.

Analysis

Gilead Sciences (GILD) has demonstrated exceptional performance in 2025, with its shares appreciating 36% year-to-date, including dividends, significantly outpacing the S&P 500's total return and reaching all-time highs. This strong momentum is primarily driven by robust Q2 results and upwardly revised corporate guidance, signaling sustained operational strength.

The company's resilient HIV portfolio, coupled with recent FDA approvals and the delayed exclusivity expiration for key drug Biktarvy, underpins its long-term growth prospects and strengthens its market position. These strategic advantages contribute to an attractive valuation, supporting the current bullish sentiment.

Technical analysis further reinforces the positive outlook, projecting potential near-term upside to $150 and a longer-term target of $185. Analysts maintain a "buy" rating on GILD, citing solid fundamentals, positive earnings momentum, and sector-leading technical strength ahead of Q3 earnings.

Key Decisions for Investors

• Investors should consider GILD for potential capital appreciation given its 36% YTD return and technical targets of $150 near-term and $185 longer-term.
• Monitor upcoming Q3 earnings for continued positive momentum and any shifts in corporate guidance or regulatory landscape, especially regarding its HIV portfolio.
• Evaluate GILD's current valuation against its projected growth and sector peers, considering the extended exclusivity of key drugs like Biktarvy as a long-term value driver.